CoChat

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

Background The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences. Method For this systematic review and meta-analysis, we searched MEDLINE for large-scale blood pressure lowering trials, published between Jan 1, 1966, and July 7, 2015, and we searched the medical literature to identify trials up to Nov 9, 2015. All randomised controlled trials of blood pressure lowering treatment were eligible for inclusion if they included a minimum of 1000 patient-years of follow-up in each study arm. No trials were excluded because of presence of baseline comorbidities, and trials of antihypertensive drugs for indications other than hypertension were eligible. We extracted summary-level data about study characteristics and the outcomes of major cardiovascular disease events, coronary heart disease, stroke, heart failure, renal failure, and all-cause mortality. We used inverse variance weighted fixed-effects meta-analyses to pool the estimates. Results We identified 123 studies with 613,815 participants for the tabular meta-analysis. Meta-regression analyses showed relative risk reductions proportional to the magnitude of the blood pressure reductions achieved. Every 10 mm Hg reduction in systolic blood pressure…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)01225-8

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 78 references

Cited by

See all 3,755

Metadata

Authors
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K.
Affiliations
  • The George Institute for Global Health (GB)
  • University of Oxford (GB)
  • The University of Sydney (AU)
Corresponding author
Rahimi, Kazem
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-03
Volume
387
Issue
10022
Pages
957-967
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2198866495
Cited by
3,755
References
77
Citations by year
2026: 347 · 2025: 374 · 2024: 391 · 2023: 380 · 2022: 397 · 2021: 428 · 2020: 398 · 2019: 350 · 2018: 298 · 2017: 248 · 2016: 137
FWCI
39.14
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
National Institute for Health and Care Research (CDF-2013-06-012, CL-2012-06-001)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
blood pressure reduction, antihypertensive drugs, cardiovascular disease prevention, all-cause mortality, coronary artery disease, stroke, heart failure, renal failure, baseline systolic blood pressure, diabetes mellitus, chronic kidney disease, cardiovascular risk reduction, meta-regression
MeSH terms
Antihypertensive Agents, Cardiovascular Diseases, Humans, Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01225-8
The paper
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(15)01225-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.